Rc(=o)n Containing (i.e., Carboxamide) (r Is C Or H) Patents (Class 514/563)
-
Patent number: 8680145Abstract: The invention describes methods and compositions for treating fear of medical procedures comprising administering proglumide to a patient having fear of medical procedures, followed by subjecting the patient to the fear-inducing medical procedure. Representative examples of fear of medical procedures that can be treated according to the methods and compositions described herein include: dental phobia, fear of needles, fear of surgery, and fear of childbirth.Type: GrantFiled: April 5, 2013Date of Patent: March 25, 2014Assignee: College of William and MaryInventor: Jason P. McDevitt
-
Publication number: 20140079811Abstract: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.Type: ApplicationFiled: May 7, 2013Publication date: March 20, 2014Inventor: Elliott C. Lasser
-
Patent number: 8673974Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, X, X1, s and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.Type: GrantFiled: November 11, 2011Date of Patent: March 18, 2014Assignee: Novartis AGInventors: Gary Mark Coppola, Rajeshri Ganesh Karki, Toshio Kawanami
-
Patent number: 8669206Abstract: The present invention provides an arthropod pests control composition comprising, as active ingredients, 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and a compound of formula (A); a method of controlling arthropod pests, which comprises applying effective amounts of 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and a compound of formula (A) to a plant or growing site of plant; and so on.Type: GrantFiled: November 18, 2010Date of Patent: March 11, 2014Assignee: Sumitomo Chemical Company, LimitedInventors: Miki Murakami, Shigeru Saito
-
Patent number: 8669205Abstract: The present invention provides: a composition for controlling plant diseases comprising, as active ingredients, 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and tolclofos-methyl; a method for controlling plant diseases which comprises applying effective amounts of 4-oxo-4-[(2-phenylethyl) amino]-butyric acid and tolclofos-methyl to a plant or soil for growing plant; and so on.Type: GrantFiled: May 21, 2010Date of Patent: March 11, 2014Assignee: Sumitomo Chemical Company, LimitedInventor: Makoto Kurahashi
-
Publication number: 20140066510Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.Type: ApplicationFiled: August 2, 2013Publication date: March 6, 2014Inventors: Mark J. Redmond, David A. Fielder
-
Patent number: 8658695Abstract: The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. Preferred delivery agents include, but are not limited to, N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). The invention also provides methods of preparing the disodium salt, ethanol solvate, and hydrate and compositions containing the disodium salt, ethanol solvate, and/or hydrate.Type: GrantFiled: May 25, 2012Date of Patent: February 25, 2014Assignees: Emisphere Technologies, Inc., Novartis AGInventors: William Elliott Bay, Rajesh K. Agarwal, Kiran Chaudhary, Shingai Majuru, Michael M. Goldberg, JoAnne P. Corvino, Moise Azria, Joseph Ault, Simon D. Bateman, Subash Patel, Joseph Sikora, Rebecca F. Yang, Joseph Zielinski
-
Patent number: 8658566Abstract: The present invention provides: a composition for controlling plant diseases comprising, as active ingredients, 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and ethaboxam; a method for controlling plant diseases which comprises applying effective amounts of 4-oxo-4-[(2-phenylethyl)amino]-butyric acid and ethaboxam to a plant or soil for growing plant; and so on.Type: GrantFiled: May 21, 2010Date of Patent: February 25, 2014Assignee: Sumitomo Chemical Company, LimitedInventor: Makoto Kurahashi
-
Patent number: 8653138Abstract: The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1, and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.Type: GrantFiled: July 1, 2011Date of Patent: February 18, 2014Assignee: 4SC MGInventors: Aldo Ammendola, Julia Diederichs, Johann Leban, Daniel Vitt
-
Patent number: 8653299Abstract: The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.Type: GrantFiled: March 1, 2012Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Vidyasagar Vuligonda, Richard L. Beard, Thong Vu, John E. Donello, Veena Viswanath, Michael E. Garst
-
Publication number: 20140045930Abstract: The present invention relates to assays for monitoring activity of YcfD activity, in particular, to assays for identifying modulators of YcfD activity. The present invention also relates to the use of YcfD inhibitors as antibiotics. The invention also relates to methods for introducing hydroxyarginine residues into proteins.Type: ApplicationFiled: January 30, 2012Publication date: February 13, 2014Inventors: Christopher Joseph Schofield, Chia-Hua Ho, Alexander Wolf, Wei Ge
-
Publication number: 20140038910Abstract: Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.Type: ApplicationFiled: July 17, 2013Publication date: February 6, 2014Applicant: Saint Louis UniversityInventors: Peter RUMINSKI, David GRIGGS
-
Publication number: 20140031380Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 19, 2013Publication date: January 30, 2014Applicant: THERAVANCE, INC.Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, John R. Jacobsen, Priscilla Van Dyke
-
Publication number: 20140030332Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: January 6, 2012Publication date: January 30, 2014Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Mark S. Fineman
-
Publication number: 20140023615Abstract: The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer.Type: ApplicationFiled: March 29, 2012Publication date: January 23, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Stephen I-Hong Hsu
-
Patent number: 8633228Abstract: A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(?G1)-Q1 (wherein G1 and G2 represent an oxygen atom or the like, Q1 represents a phenyl group which may have a substituent, a heterocyclic group which may have a substituent, or the like), or the like, Q2 represents a phenyl group or the like, G3 represents an oxygen atom or the like, and R1 and R2 each independently represent a hydrogen atom, a C1-C6 alkyl group, or a group represented by -L-D, or the like (provided that at least either R1 or R2 represents a group represented by -L-D); as an active ingredient exhibits an excellent effect.Type: GrantFiled: June 29, 2009Date of Patent: January 21, 2014Assignee: Mitsui Chemicals Agro, Inc.Inventors: Yumi Kobayashi, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Hidenori Daido, Yusuke Takahashi, Shinichi Banba
-
Patent number: 8633192Abstract: Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed.Type: GrantFiled: December 14, 2007Date of Patent: January 21, 2014Assignee: TIMA FoundationInventors: Markus Matuschka-Greiffenclau, Haruhiko Inufusa
-
Publication number: 20140018424Abstract: L-citrulline or a nutraceutically or pharmaceutically acceptable salt thereof for reducing the kinetics of tumour development or reduce the incidence of tumours in aged humans and animals.Type: ApplicationFiled: January 10, 2012Publication date: January 16, 2014Applicant: UNIVERSITE PARIS DESCARTESInventors: Christophe Moinard, Servane Le Plenier, Agathe Raynaud-Simon, Vickie Baracos, Luc Cynober
-
Publication number: 20140017329Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.Type: ApplicationFiled: July 10, 2013Publication date: January 16, 2014Inventor: Shaker A. Mousa
-
Publication number: 20140011857Abstract: The invention provides for novel compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer.Type: ApplicationFiled: September 12, 2011Publication date: January 9, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Robert A. Casero, Ian Bytheway, Patrick M. Woster
-
Publication number: 20130344083Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.Type: ApplicationFiled: March 14, 2013Publication date: December 26, 2013Inventors: C. Wilson Xu, Yasuyo Urasaki
-
Publication number: 20130345306Abstract: The invention provides methods to treat oxygen-induced retinopathy using complement factor C3aR antagonists.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: John T. FLYNN, Quan WEN, Takayuki NAGASAKI
-
Patent number: 8614249Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.Type: GrantFiled: November 8, 2010Date of Patent: December 24, 2013Assignee: Prototype Bioforum Ltd.Inventors: Paul Sherwood, David Keith Davies
-
Patent number: 8614205Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.Type: GrantFiled: June 2, 2012Date of Patent: December 24, 2013Inventors: Richard D Wood, William Welsh
-
Publication number: 20130336902Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
-
Publication number: 20130336903Abstract: A personal care composition is disclosed comprising a pH tuneable gellant. The pH tuneable gellant has a formula of: wherein R1 and R2 are aminofunctional end-groups; L1 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L1, R1 or R2 comprises a pH-sensitive group; wherein R5 is an aminofunctional moiety; L2 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L2 or R5 comprises a pH-sensitive group; and mixtures of [I] and [II]. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion or may comprise one or more actives or agents.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
-
Patent number: 8609642Abstract: The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can be a topical skin treatment composition that includes polyethylene glycol (PEG), triclosan, one or more of a salicylate, bronopol, and an acrylic emulsion, and, optionally, a solvent.Type: GrantFiled: June 3, 2010Date of Patent: December 17, 2013Assignee: Ex-Tek, LLCInventor: Richard James Whitbourne
-
Publication number: 20130331328Abstract: Small molecule inhibitors of AGBL2 are provided, as well as methods of using the inhibitors to treat or prevent cancer and neurologic disorders.Type: ApplicationFiled: February 14, 2012Publication date: December 12, 2013Applicant: GEORGETOWN UNIVERSITYInventors: Stephen W. Byers, Sivanesan Dakshanamurthy, Ziad Sahab
-
Publication number: 20130323271Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: May 30, 2013Publication date: December 5, 2013Inventors: Mathai Mammen, Adam D. Hughes
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Publication number: 20130310386Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: ApplicationFiled: November 10, 2011Publication date: November 21, 2013Applicant: Fibrotech Therapeutics Pty LtdInventors: Darren James Kelly, David Stapleton
-
Patent number: 8580852Abstract: The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA 2 and GVIA 1PLA 2) and one human secretory phospholipase A2 (GV sPLA 2) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA 2 inhibitors. A derivative based on the ethyl ester of an ether pseudodipeptide is the first 2-oxoamide, which preferentially inhibits GVIA iPLA 2. The effect of 2-oxoamides on the generation of arachidonic acid from RAW 264.7 macrophages was also studied. It was found that selective GIVA cPLA 2 inhibitors preferentially inhibited cellular arachidonic acid release; in which one pseudodipeptide gave an IC50 value of 2 ?M.Type: GrantFiled: April 19, 2010Date of Patent: November 12, 2013Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, George Kokotos, Violetta Constantinou-Kokotou
-
Patent number: 8580854Abstract: Accelerated formation of advanced glycation/lipoxidation end products (AGEs/ALEs) has been implicated in the pathogenesis of various diabetic complications. Several natural and synthetic compounds have been proposed and tested as inhibitors of AGE/ALE formation. We have previously reported the therapeutic effects of several new AGE/ALE inhibitors on the prevention of nephropathy and dyslipidemia in streptozotocin (STZ)-induced diabetic rats. In this study, we investigated the effects of various concentrations of LR-90 on the progression of renal disease and its effects on AGE and receptor for AGE (RAGE) protein expression on the kidneys of diabetic STZ-rats. In vitro studies were also performed to determine if LR-90 could inhibit the expression of various pro-inflammatory mediators in human monocytic cells.Type: GrantFiled: November 9, 2006Date of Patent: November 12, 2013Assignee: City of HopeInventors: Samuel Rahbar, Rama Natarajan
-
Publication number: 20130295187Abstract: A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof.Type: ApplicationFiled: July 5, 2013Publication date: November 7, 2013Inventor: Shaker A. Mousa
-
Publication number: 20130289109Abstract: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 3, 2013Publication date: October 31, 2013Inventors: Takayuki KAWAGUCHI, Sumihiro NOMURA, Mikiko TSUKIMOTO, Toshiyuki KUME, Ila SIRCAR
-
Publication number: 20130289118Abstract: The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl]aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain.Type: ApplicationFiled: March 29, 2013Publication date: October 31, 2013Applicant: Uniwersytet JagiellonskiInventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
-
Patent number: 8569377Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.Type: GrantFiled: December 9, 2010Date of Patent: October 29, 2013Assignees: The United States of America as Represented by the Department of Veteran Affairs, University of Maryland, BaltimoreInventor: J. Marc Simard
-
Patent number: 8569381Abstract: The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.Type: GrantFiled: May 22, 2009Date of Patent: October 29, 2013Assignee: Targacept, Inc.Inventors: Steven M. Toler, David A. Hosford
-
Publication number: 20130281394Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Publication number: 20130281387Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Patent number: 8557867Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.Type: GrantFiled: June 20, 2008Date of Patent: October 15, 2013Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Maryland, BaltimoreInventor: J. Marc Simard
-
Patent number: 8552033Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.Type: GrantFiled: December 17, 2008Date of Patent: October 8, 2013Assignee: SANOFIInventors: Stephanie Hachtel, Juergen Dedio, Stephen Shimshock, Carolina Lanter
-
Patent number: 8552067Abstract: Provided herein are bioactive agents comprising a compound that inhibits the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR) and that is linked to a macromolecule that interacts with a cell that expresses CFTR. The bioactive agents described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea.Type: GrantFiled: December 19, 2007Date of Patent: October 8, 2013Assignee: The Regents of the University of CaliforniaInventors: Alan S. Verkman, Nitin D. Sonawane
-
Publication number: 20130261185Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.Type: ApplicationFiled: October 8, 2012Publication date: October 3, 2013Applicant: Glaxo Group LimitedInventors: Alessandra Gaiba, Mark Patrick Healy, Christopher Norbert Johnson, Susan Roomans, Steven James Stanway, Martin Edward Swarbrick
-
Patent number: 8546451Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: GrantFiled: February 23, 2010Date of Patent: October 1, 2013Assignee: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20130251787Abstract: Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxgygenase activating protein (FLAP) inhibitors.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark R. Nicolls, Wen Tian, Jayakumar Rajadas
-
Publication number: 20130253060Abstract: Use of sPLA2 inhibitors (for example, BPPA (5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino) pentanoic acid)) within about 9 hours after poisoning with a liver toxin, for example, acetaminophen (APAP), was shown to increase survivorship. The inhibition of sPLA2 lead to markedly decreased progression of liver injury as reflected in lower alanine aminotransferase (ALT—a biomarker for liver injury) levels, and to significantly higher survival rates. Similar treatment in human patients suffering from hepatotoxicity will be effective in increasing survival, and treatment with other sPLA2 inhibitors will also be effective in decreasing liver damage and mortality.Type: ApplicationFiled: September 13, 2012Publication date: September 26, 2013Inventor: Harihara M. Mehendale
-
Publication number: 20130237542Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: ApplicationFiled: October 17, 2011Publication date: September 12, 2013Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyeong Lee, Mi Sun Won, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Ki Hoon Lee, Chang Woo Lee, Jung Joon Lee, Kyung Sook Chung, Bo Kyung Kim, Yinglan Jin, Seung-hee Lee
-
Publication number: 20130237604Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).Type: ApplicationFiled: April 18, 2013Publication date: September 12, 2013Applicant: Lasser Family Partnership, L.P.Inventors: Elliott C. Lasser, Kenneth H. Lasser
-
Patent number: RE44704Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.Type: GrantFiled: September 13, 2012Date of Patent: January 14, 2014Assignee: Immunogen Inc.Inventors: Ravi V. J. Chari, Walter A. Blättler